Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

They focused on a protein called BACE1, which is a key enzyme in the production of amyloid-beta. In the first part of the ...

The drug works by targeting beta amyloid -- a protein that builds up in the brains of people with Alzheimer's disease and is thought to be the triggering event leading to neuronal dysfunction and cell ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

"Our findings suggest that perhaps by targeting oligodendrocytes, we could more effectively stop amyloid beta production without causing other issues and thereby more effectively and safely slow ...

Researchers discover protective pathway against Alzheimer's in mice Alzheimer's disease is marked by the gradual degeneration ...

Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

Alzheimer’s disease is the most common brain condition in older adults worldwide and a leading cause of dementia. Despite ...

The new measures align with recently published proper use recommendations for Leqembi, Eisai’s and Biogen’s FDA-approved anti-amyloid beta therapy. Both Leqembi and Eli Lilly’s Kisunla ...

The acquisition will give AbbVie control of an Alzheimer’s disease drug candidate Aliada in-licensed from Johnson & Johnson to try to improve on the first generation of anti-amyloid-beta antibodies.

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood ...

New St Vincent Institute research has found the treatment of Alzheimer’s disease will take more than a “magic bullet”.